<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010915</url>
  </required_header>
  <id_info>
    <org_study_id>202002467A3</org_study_id>
    <nct_id>NCT05010915</nct_id>
  </id_info>
  <brief_title>TBS,TMS, Suicidal Ideation, Magnetic Resonance Imaging, Dorsolateral Prefrontal Cortex, Ventrolateral Prefrontal Cortex</brief_title>
  <official_title>Theta Burst Stimulation, Transcranial Magnetic Stimulation, Late Life Depression, Suicidal Ideation, Functional Magnetic Resonance Imaging, Dorsolateral Prefrontal Cortex, Ventrolateral Prefrontal Cortex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique, its&#xD;
      approved therapeutic indication is high-frequency stimulation to the left dorsolateral&#xD;
      prefrontal cortex (DLPFC) for treatment resistant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      investigators design a prospective three-year study to exam the effect of TBS on reducing&#xD;
      suicidality targeted at left DLPFC vs VLPFC, and guided by task fMRI neuronavigation and&#xD;
      sham. Investigators will adopt personalized left DLPFC and VLPFC localization from baseline&#xD;
      task fMRI data. Due to the global brain atrophic changes in the older adults, this issue has&#xD;
      been even more important. Investigators will enroll 163 late life depression cases, they will&#xD;
      be randomly allocated to either DLPFC group (65 cases), or VLPFC group (65 cases) and sham&#xD;
      group (33 cases). To sum up, investigators seek to evaluate the impact of an acute course of&#xD;
      TBS guided by tsked fMRI neuronavigation on suicidal ideation, and through follow-up for 6&#xD;
      months, investigators expect to examine (1) suicidal ideation, structural and functional&#xD;
      brain differences, inflammatory markers pre/post TBS treatment, explore the link between the&#xD;
      mechanism underlying of TBS on brain connectivity and therapeutic effects (2) Association of&#xD;
      suicide ideation and neurocognitive function, inflammatory factors and brain imaging data.&#xD;
      Exploratory analysis will assess suicide ideation as mediator in the association of&#xD;
      neurocognitive deficit and functional connectivity or neurocognitive deficit as mediator in&#xD;
      the association of suicide ideation and brain imaging data (3) The trajectories of suicidal&#xD;
      ideation in late life depression, to analysis whether the association of cognitive&#xD;
      dysfunction and suicidal ideation occurs across time and the prediction of neurocognitive&#xD;
      function.(4) Explore the association of suicidal ideation the depression severity, to test if&#xD;
      suicidal ideation could be an independent treatment target (5) Investigate the plausible&#xD;
      predictors of neuropsychological profiles or neuroimaging findings associated to the effect&#xD;
      of TBS in reducing suicidal ideation, which could provide a more efficient strategy for&#xD;
      suicide prevention in the elder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beck Scale for Suicide Ideation (BSSI) at baseline</measure>
    <time_frame>baseline(1 week before treatment)</time_frame>
    <description>the severity of suicide ideation(the score range from 0-38,the higher score indicates higher severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Scale for Suicide Ideation (BSSI)at the 1st month</measure>
    <time_frame>the 1st month (4 weeks after baseline)</time_frame>
    <description>the severity of suicide ideation(the score range from 0-38,the higher score indicates higher severity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Scale for Suicide Ideation (BSSI)at the 3rd month</measure>
    <time_frame>the 3rd month(12 weeks after baseline)</time_frame>
    <description>the severity of suicide ideation(the score range from 0-38,the higher score indicates higher severity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Scale for Suicide Ideation (BSSI)at the 6th month</measure>
    <time_frame>the 6th month(24 weeks after baseline)</time_frame>
    <description>the severity of suicide ideation(the score range from 0-38,the higher score indicates higher severity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline), the 3rd moth(12 weeks after baseline), and the 6th month(24 weeks after baseline)</time_frame>
    <description>the severity of depression(the score range from 0-15,the higher score means worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>structural and functional connectivity</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>Brain MRI connectivity change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI T1</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>Brain structural volumes (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional MRI (resting-state/biological motion task) - BOLD signal</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI which reflects the neural activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion Tensor Imaging (DTI) - FA</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons.reflects the neural activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Learning &amp; Memory:</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline) and the 6th month(24 weeks after baseline)</time_frame>
    <description>Word list of Wechsler Memory Scale-III Face memory task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>IL-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-2</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-10</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1β</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>IL-1β</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive protein</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortisol</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thyrotropin</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>TSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor</measure>
    <time_frame>baseline(1 week before treatment), the 1st month(4 weeks after baseline)</time_frame>
    <description>BDNF</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">163</enrollment>
  <condition>Late Life Depression</condition>
  <arm_group>
    <arm_group_label>dorsolateral prefrontal cortex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age &gt; 50 years.&#xD;
Major depressive disorder (MDD).&#xD;
Right handiness&#xD;
with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ventrolateral prefrontal cortex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age &gt; 50 years.&#xD;
Major depressive disorder (MDD).&#xD;
Right handiness&#xD;
with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Age &gt; 50 years.&#xD;
Major depressive disorder (MDD).&#xD;
Right handiness&#xD;
with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial magnetic stimulation</intervention_name>
    <description>Transcranial magnetic stimulation</description>
    <arm_group_label>dorsolateral prefrontal cortex</arm_group_label>
    <arm_group_label>sham comparator</arm_group_label>
    <arm_group_label>ventrolateral prefrontal cortex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 50 years.&#xD;
&#xD;
          2. Major depressive disorder (MDD).&#xD;
&#xD;
          3. Right handiness&#xD;
&#xD;
          4. with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at&#xD;
             least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent.&#xD;
&#xD;
          2. Dementia, as defined by MoCA 23/24. Other major mental or current psychotic symptoms&#xD;
&#xD;
          3. Active current suicidal intent as evidenced or the endorsement of an actual attempt,&#xD;
             interrupted attempt,&#xD;
&#xD;
          4. Have known preexisting noise-induced hearing loss, concurrent treatment with ototoxic&#xD;
             medications, or with cochlear implants are on medications known to lower seizure&#xD;
             threshold.&#xD;
&#xD;
          5. Alcohol or other substances abuse of or dependence on within the past 3 months Organic&#xD;
             brain, head trauma,&#xD;
&#xD;
          6. Elevated risk of seizure due to TBI&#xD;
&#xD;
          7. Participation in concurrent clinical trial&#xD;
&#xD;
          8. Non-correctable clinically significant sensory impairment (i.e., cannot hear well&#xD;
             enough to cooperate with interview).&#xD;
&#xD;
          9. Unstable medical illness, including delirium, malignancy, uncontrolled diabetes&#xD;
             mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk&#xD;
             factors that are not under medical management. Unstable cardiac disease or recent&#xD;
             (&lt;3m) myocardial infarction&#xD;
&#xD;
         10. Mental implement in the brain, claustrophobia&#xD;
&#xD;
         11. Ever received ECT, TMS Consent procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shwu-Hua Lee</last_name>
    <role>Study Chair</role>
    <affiliation>ChungGung memorial hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shwu-Hua Lee</last_name>
    <phone>03-3281200</phone>
    <phone_ext>3839</phone_ext>
    <email>shlee@cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hsueh-ching tsai, bachelor</last_name>
    <phone>03-3281200</phone>
    <phone_ext>3839</phone_ext>
    <email>stacy.tsai409@gmail.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMS</keyword>
  <keyword>TBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

